• RSVP: Japan Life Science Showcase & Kyoto-iCAP Innovation Session

    Please confirm your attendance for the Japan Life Science Showcase and Kyoto-iCAP "Translating Kyoto Science into Global Ventures" Session at RESI San Diego 2026. Review the event details below and submit your RSVP.
  • 🔬 KBIC Session – Japan Life Science Showcase –

    📅 Date & Time: Monday, June 22, 1:00 - 3:00pm

    📍 Location: JULEP Venue San Diego (1735 Hancock St, San Diego, CA 92101)

     

    As Title Sponsor of RESI San Diego 2026, Kobe Biomedical Innovation Cluster (KBIC), Japan's largest biomedical innovation cluster, is proud to host the Japan Life Science Showcase, a dedicated pitching session featuring a curated group of emerging Japanese life science innovators.

    A total of 8 companies representing promising innovations across life sciences and healthcare sectors will deliver rapid-fire presentations. Following the presentations, participating companies will engage in a live Q&A session with a panel of global investor and industry judges.

    The showcase offers attendees a unique opportunity to discover cutting-edge innovations emerging from Japan's dynamic life science ecosystem and connect directly with the entrepreneurs, investors, and ecosystem leaders driving their growth. Investors, strategic partners, and industry professionals interested in exploring partnership and investment opportunities are warmly invited to attend.

     

    🔬 Kyoto-iCAP Session – Translating Kyoto Science into Global Ventures –

    📅 Date & Time: Monday, June 22, 3:00 - 4:00pm

    📍 Location: JULEP Venue San Diego (1735 Hancock St, San Diego, CA 92101)

     

    Kyoto University Innovation Capital Co., Ltd. (Kyoto-iCAP) and Kyoto University will introduce Kyoto’s growing biotech innovation ecosystem and showcase emerging life science ventures developing transformative technologies in regenerative medicine, cell therapy, nephrology, pain treatment and radiopharmaceuticals. The session is designed to foster connections between global investors, strategic partners, and leading Kyoto University-originated startups.

  • Are you already registered for RESI San Diego 2026?*
  • Please confirm your RSVP:*
    • ⬇️ Learn More About the 8 Companies Pitching in Japan Life Science Showcase 
    • RadioNano Therapeutics is a Kyoto University spinout developing next-gration nanomedicines for Boron Neutron Capture Therapy (BNCT). Its lead program, RN-501, is designed to overcome key limitations of current BNCT agents through superior tumor accumulation and retention, enabling the treatment of deep-seated, recurrent, metastatic, and diffuse cancers that remain challenging to address with existing therapies.

      Built on world-leading expertise in BNCT and nanotechnology, RadioNano Therapeutics is advancing a novel precision radiotherapy platform with the potential to expand the clinical utility of BNCT beyond its current applications. The company is progressing RN-501 toward clinical development and global commercialization to address significant unmet medical needs and unlock substantial opportunities across large oncology markets, with the goal of improving outcomes for patients with difficult-to-treat cancers worldwide.

      Hiuchi Pharma is a biotechnology company developing first-in-class therapeutics targeting TRPC3/C6 channels for pulmonary arterial hypertension (PAH) and other cardiovascular and renal diseases. Its lead program, L862, is an orally available small molecule designed to inhibit pathological vascular remodeling, a fundamental driver of disease progression that remains inadequately addressed by current therapies. Built on pioneering research that established the critical role of TRPC3/C6 in cardiovascular remodeling, Hiuchi Pharma is advancing a novel disease-modifying approach for patients with serious and life-threatening chronic conditions. Beyond PAH, the company sees broad potential for TRPC3/C6-targeted therapies across multiple indications, including heart failure and kidney diseases. Through its innovative pipeline, Hiuchi Pharma aims to improve long-term outcomes while addressing significant unmet medical needs.

      ANT5 is a medical technology company developing the world’s first multimodal brain monitoring platform for patients with severe brain injury. Its proprietary system integrates EEG, intracranial pressure, cerebral oxygenation, blood flow, and brain temperature monitoring into a single device, enabling continuous real-time assessment of brain status and early detection of secondary brain injury. Built on decades of neuroscience and neurocritical care research, ANT5 is addressing a critical unmet need in the management of traumatic brain injury, stroke, and other acute neurological conditions, where timely intervention can significantly impact patient outcomes. Through advanced monitoring technologies and future AI-driven analytics, the company aims to support clinical decision-making, improve neurological recovery, and establish a new standard of care in neurocritical medicine worldwide.


      Juntendo University is developing a first-in-class in vivo direct reprogramming gene therapy for Type 1 Diabetes, with the goal of replacing lifelong insulin dependence through a single disease-modifying treatment.Its proprietary OKAP platform utilizes patented K-Factor technology to directly convert liver cells into functional insulin-producing cells in vivo, eliminating the need for cell transplantation. Delivered through AAV- or LNP-based gene therapy, the approach is designed to restore physiological glucose regulation, reduce the burden of daily insulin management, and potentially achieve long-term insulin independence.Supported by compelling preclinical data, the platform has the potential to transform diabetes treatment and may be expanded to additional indications, including insulin-dependent Type 2 Diabetes and other diseases addressable through in vivo cellular reprogramming.

      Cellford is a regenerative medicine company developing the Injectable Cell Scaffold (ICS), a novel platform designed to overcome one of the most significant limitations of cell therapy: poor cell retention and survival at the target site. The technology is initially being developed for patients with critical limb ischemia (CLI), a severe vascular disease that can lead to limb amputation and has limited treatment options. By enabling long-term retention of therapeutic cells and sustained release of angiogenic factors, ICS promotes robust blood vessel formation and enhanced tissue regeneration. Developed as a medical device compatible with culture-free autologous cell therapies, the platform offers a scalable and cost-effective approach to regenerative medicine. CellFold aims to improve outcomes for patients with ischemic diseases while expanding the potential of cell-based therapies across multiple clinical applications.

      FELIQS is a clinical-stage ophthalmology company developing innovative therapies for retinal and corneal diseases with significant unmet medical needs. The company is advancing a diversified pipeline targeting conditions including retinopathy of prematurity (ROP), pterygium, and dry age-related macular degeneration (Dry AMD), addressing diseases that currently have limited or no effective treatment options.

      Leveraging novel mechanisms targeting oxidative stress, fibrosis, and angiogenesis, FELIQS is developing patient-friendly therapies designed to reduce dependence on invasive procedures while improving long-term visual outcomes. Through its innovative ophthalmology pipeline, FELIQS aims to preserve vision, prevent blindness, and improve quality of life for patients worldwide.

      United Immunity is a clinical-stage biotechnology company developing next-generation immunotherapies through its proprietary Myeloid Targeting Platform™. The company selectively delivers therapeutic payloads to macrophages and dendritic cells, enabling innovative approaches in oncology, autoimmune diseases, and fibrosis. Its pipeline includes a clinical-stage TLR7/8 agonist program (UI-102) and an in vivo CAR-macrophage platform, supported by strategic collaborations and strong non-dilutive funding.

      VC Cell Therapy (VCCT) is a seed/growth-stage biotechnology company developing a portfolio of ex vivo and in vivo cell therapy solutions for ocular diseases. We are a proud member of the Kobe Eye Center Initiative, a consortium of organizations that unifies research, clinical practice, and patient care, for the benefit of patients suffering from ocular diseases. Under the guiding principle of “Total solutions for every patient”, we challenge ourselves to think of every possible way to improve the lives of visually impaired people. 

       

    • ⬇️ Learn More About the 5 Companies Pitching in Kyoto-iCAP Session 

    • Shinobi Therapeutics
      is a biotechnology company developing next-generation cell therapies powered by its proprietary SAFE-Harbor Engineered Cell (SEC) platform, which enables precise genetic engineering of immune cells to improve safety, persistence, and therapeutic efficacy. The company's technology is designed to overcome key limitations of current cell therapies, including immune rejection, limited durability, and manufacturing complexity. By engineering immune cells with enhanced functionality and reduced immunogenicity, Shinobi aims to create scalable off-the-shelf and autologous cell therapy products for cancer, autoimmune disorders, and other serious diseases. Leveraging expertise in gene editing, immunology, and cell engineering, Shinobi Therapeutics is advancing a pipeline of innovative cellular medicines intended to expand patient access and improve outcomes across multiple therapeutic areas.

      Rege Nephro is a clinical-stage biotechnology company developing novel therapies for chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD) using technologies derived from Kyoto University's Center for iPS Cell Research and Application (CiRA). The company is advancing RN-032, an iPSC-derived nephron progenitor cell therapy designed to slow the progression of CKD and reduce the need for dialysis or kidney transplantation. In parallel, Rege Nephro is developing RN-014, a small-molecule therapeutic for ADPKD identified through proprietary kidney organoid disease models. By combining regenerative medicine, iPSC technology, and advanced disease modeling, Rege Nephro aims to deliver transformative treatments for patients with kidney diseases, an area with significant unmet medical need and limited therapeutic options.

      BTB Therapeutics is a clinical-stage biotechnology company developing novel RNA-targeted therapeutics and non-opioid pain medicines based on the pioneering transcriptomics research of Professor Masatoshi Hagiwara at Kyoto University. The company's lead program, ENDOPIN, is a first-in-class non-opioid analgesic designed to provide potent pain relief without the dependence and abuse risks associated with opioid therapies. In addition to its pain management program, BTB Therapeutics is advancing a pipeline of small molecules that modulate RNA splicing and RNA processing pathways for the treatment of rare genetic diseases and to enhance the efficacy of cancer immunotherapy. By leveraging proprietary transcriptomics and RNA biology platforms, BTB Therapeutics aims to develop transformative therapies that address significant unmet medical needs across multiple therapeutic areas.

      NewCo from Center for iPS Cell Research and Application (CiRA) is being developed based on technologies originating from the Center for iPS Cell Research and Application (CiRA) at Kyoto University, one of the world's leading institutes dedicated to induced pluripotent stem (iPS) cell research and regenerative medicine. Established under the leadership of Dr. Shinya Yamanaka, recipient of the 2012 Nobel Prize in Physiology or Medicine for the discovery of iPS cells, CiRA has been at the forefront of advancing stem cell technologies for regenerative medicine, drug discovery, and the treatment of intractable diseases.

      Since its founding, CiRA has built a globally recognized research ecosystem focused on translating breakthrough scientific discoveries into real-world medical applications. Through pioneering work in iPS cell biology, cell therapy, disease modeling, and drug development, the institute has contributed to numerous innovations that are shaping the future of regenerative medicine and precision healthcare. The venture presented at RESI San Diego represents the next generation of innovation emerging from Kyoto University's world-class research community and reflects CiRA's mission of transforming cutting-edge science into meaningful patient impact.

      Orizuru Therapeutics is a regenerative medicine company developing next-generation cell therapies based on induced pluripotent stem cell (iPSC) technologies originating from the T-CiRA collaboration between Kyoto University's Center for iPS Cell Research and Application (CiRA) and Takeda Pharmaceutical Company. Founded in 2021, the company is advancing innovative regenerative medicine programs for severe type 1 diabetes and chronic heart failure, two areas with significant unmet medical need.

      Its lead pipeline includes OZTx-410, an iPSC-derived pancreatic islet cell therapy designed to restore insulin production in patients with type 1 diabetes, and OZTx-556, an iPSC-derived cardiomyocyte therapy aimed at regenerating damaged heart tissue in patients with severe heart failure. Orizuru recently initiated clinical development of OZTx-410, marking an important milestone in the translation of iPSC research into real-world therapies. By combining cutting-edge stem cell science, scalable manufacturing technologies, and translational expertise, Orizuru Therapeutics aims to deliver transformative regenerative medicine products that improve outcomes for patients with serious chronic diseases.

    • ⬇️ Learn More About Kobe Biomedical Innovation Cluster (KBIC) 
    • Kobe Biomedical Innovation Cluster: Gateway to Japan's Largest Biocluster Innovation Community 


      The Kobe Biomedical Innovation Cluster (KBIC)
      was established as part of Kobe’s post-earthquake revitalization strategy and has since grown into Japan’s largest biomedical cluster. Founded in 1998, KBIC now brings together more than 370 companies, research institutes, universities, and specialized hospitals, creating a highly collaborative environment for advancing medical devices, regenerative medicine, pharmaceuticals, diagnostics, and digital health technologies. Its mission is to accelerate innovation, support commercialization, and strengthen Japan’s life science ecosystem by connecting industry, academia, and clinical institutions.

      Located on Port Island with convenient access to Kobe Airport and high-speed rail, KBIC offers a dense concentration of resources including advanced research facilities, hospital and clinical infrastructure, wet labs, shared equipment, and rental lab or office space. Through the Foundation for Biomedical Research and Innovation at Kobe (FBRI), the cluster provides extensive support services such as regulatory guidance, startup incubation, business development assistance, and international partnership programs. Together, these assets make KBIC one of Asia’s leading hubs for life science innovation and global collaboration.

      >> For more information, please visit https://www.fbri-kobe.org/kbic/english. 

    • ⬇️ Learn More About Kyoto University Innovation Capital (Kyoto-iCAP) 
    • Kyoto University Innovation Capital Co., Ltd. (Kyoto-iCAP) was established in 2014 as the venture investment and commercialization arm of Kyoto University, one of Japan's most prestigious research institutions. Kyoto-iCAP was created to accelerate the translation of groundbreaking academic discoveries into successful ventures by supporting researchers, entrepreneurs, and startups emerging from Kyoto University's world-class research ecosystem. Through investment, venture creation, and strategic support, Kyoto-iCAP plays a central role in advancing innovation across life sciences, healthcare, advanced materials, artificial intelligence, and deep technology sectors.

      Leveraging Kyoto University's long history of scientific excellence and Nobel Prize-winning research, Kyoto-iCAP works closely with faculty, researchers, students, investors, and industry partners to identify promising technologies and guide them toward commercialization. The organization provides seed and early-stage funding, business development support, intellectual property strategy, management recruitment, and access to global networks of investors and strategic partners. Through these efforts, Kyoto-iCAP has helped launch and support numerous university-originated ventures addressing critical challenges in healthcare and beyond.

      As Kyoto continues to strengthen its position as one of Japan's leading centers for innovation and entrepreneurship, Kyoto-iCAP serves as a vital bridge between academic research and real-world impact, fostering the next generation of globally competitive startups emerging from Kyoto University's research community.

      >> For more information, please visit https://www.kyoto-unicap.co.jp/en. 

    • Should be Empty: